Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-02-28DOI: 10.1007/s12072-026-11056-w
Qiongying Xu, Jiehua Han, Jiali Zhu
{"title":"Comment on \"Inhibition of the U12-type splicing factor ZCRB1 mediates retention of the USP21 minor intron to suppress malignant progression in hepatocellular carcinoma\".","authors":"Qiongying Xu, Jiehua Han, Jiali Zhu","doi":"10.1007/s12072-026-11056-w","DOIUrl":"10.1007/s12072-026-11056-w","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1545-1546"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effect of testosterone addition to nutrition and exercise on muscle mass in men with cirrhosis: the next trial.","authors":"Vinod Arora, Sushrut Singh, Jaya Benjamin, Varsha Shasthry, Satendra Pal Singh, Guresh Kumar, Shiv Kumar Sarin","doi":"10.1007/s12072-026-11106-3","DOIUrl":"10.1007/s12072-026-11106-3","url":null,"abstract":"<p><strong>Background: </strong>Nutrition supplementation and exercise are the current approaches for managing sarcopenia in patients with cirrhosis. There are limited data on benefits, if any, of supplementing testosterone in cirrhosis with sarcopenia and frailty.</p><p><strong>Methods: </strong>127 patients with cirrhosis and sarcopenia were randomized to receive either nutrition and structured exercise with intramuscular testosterone undecanoate 1000 mg administered at 0, 6, 12, 16, 20, and 24 weeks (NExT group, n = 64) or only structured exercise and nutrition (NEx group, n = 63). Of these, 102 patients completed the 24-week study period as per protocol (NExT, n = 50; NEx, n = 52). The primary endpoint was a ≥ 10% increase in appendicular skeletal muscle index (ASMI) at 24 weeks, assessed by dual-energy X-ray absorptiometry (DEXA).</p><p><strong>Results: </strong>The mean age, MELD (median 14), CTP score (Child A 15.7%, Child B 64.7%, Child C 19.6%) were comparable between groups. On intention-to-treat analysis, a ≥ 10% increase in ASMI was achieved in 41/64 (64.1%) patients in the NExT group compared with 16/63 (25.3%) in the NEx group (p < 0.001). Similar findings were observed in the per-protocol analysis (33/50 [66%] vs. 13/52 [25%]; p < 0.001). A greater proportion of patients in the NExT group demonstrated improvement in hand-grip strength (92% vs. 67.3%, p = 0.002), 6-min walk distance (82% vs. 63.5%, p = 0.04), and reduction in serum ammonia (64% vs. 25%, p = 0.01). Liver frailty index improved significantly in the NExT group compared with the NEx group at 24 weeks (3.98 ± 0.27 to 3.32 ± 0.21 vs. 3.93 ± 0.24 to 3.68 ± 0.22, respectively; p = 0.01). Hospitalization rates were lower in the NExT group (18% vs. 34.6%, p = 0.05), with no apparent major adverse-events with testosterone use.</p><p><strong>Conclusion: </strong>The addition of testosterone therapy to nutrition and structured exercise protocols significantly improves the appendicular muscle mass, reduces frailty and need of rehospitalization in cirrhosis patients with sarcopenia and frailty.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1382-1394"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148277167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-07-27DOI: 10.1007/s12072-026-11132-1
Shi-Ping Sun, Chen-Xi Wang, Ming-Kai Yuan, Han Min
{"title":"GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials.","authors":"Shi-Ping Sun, Chen-Xi Wang, Ming-Kai Yuan, Han Min","doi":"10.1007/s12072-026-11132-1","DOIUrl":"10.1007/s12072-026-11132-1","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with unmet clinical treatment needs, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promising therapeutic potential. This study systematically evaluated the efficacy of GLP-1 RAs in treating adult MASH patients via a meta-analysis of randomized controlled trials (RCTs).</p><p><strong>Methods: </strong>Following PRISMA 2020 guidelines, we retrieved RCTs from PubMed, Embase, Cochrane Library and Web of Science. Eligible studies included adult MASH patients treated with GLP-1 RAs vs. placebo/standard care. Two reviewers independently performed literature screening, data extraction and risk-of-bias assessment (RoB 2.0). Meta-analysis was conducted using RevMan 5.4, with subgroup analyses by GLP-1 RA type and intervention duration.</p><p><strong>Results: </strong>A total of 27 RCTs involving 2,687 patients were included. GLP-1 RAs significantly increased MASH resolution without fibrosis worsening (RR = 2.56; 95% CI, [1.90, 3.44]; p < 0.00001; I<sup>2</sup> = 49%) and liver fibrosis improvement without steatohepatitis worsening (RR = 1.37; 95% CI, [1.06, 1.78]; p = 0.02; I<sup>2</sup> = 44%). Subgroup analyses showed GLP-1 RAs benefited MASH resolution across subgroups, while fibrosis improvement was only significant for multi-receptor agonists and intervention > 48 weeks. No significant changes in ALT/AST were observed (p > 0.05).</p><p><strong>Conclusions: </strong>GLP-1 receptor agonists are effective for achieving histological remission in MASH. More large-scale, long-term follow-up randomized controlled trials are urgently needed. Trial registration The protocol for our meta-analysis and systematic review was registered and recorded in PROSPERO (registration no. CRD420261287573).</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1372-1381"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-07-11DOI: 10.1007/s12072-026-11127-y
Glenn Jun Kit Ho, Asvin Selvakumar, Lucas Yang Yuxu Yeo, Mako Eguchi, Ryan Yanzhe Lim, Benedix Kuan Loon Sim, Daniel Tung, Apoorva N Sasikumar, Shirley Huey Shin Bong, Ethan Kai Jun Tham, Jia Hao Law, Eunice Xiang-Xuan Tan, Brian J Wentworth, Won-Mook Choi, Aparna Goel, David N Assis, Benjamin Nah, Vincent L Chen
{"title":"Epidemiology of primary sclerosing cholangitis in general and IBD populations: a systematic review and meta-analysis.","authors":"Glenn Jun Kit Ho, Asvin Selvakumar, Lucas Yang Yuxu Yeo, Mako Eguchi, Ryan Yanzhe Lim, Benedix Kuan Loon Sim, Daniel Tung, Apoorva N Sasikumar, Shirley Huey Shin Bong, Ethan Kai Jun Tham, Jia Hao Law, Eunice Xiang-Xuan Tan, Brian J Wentworth, Won-Mook Choi, Aparna Goel, David N Assis, Benjamin Nah, Vincent L Chen","doi":"10.1007/s12072-026-11127-y","DOIUrl":"10.1007/s12072-026-11127-y","url":null,"abstract":"<p><strong>Background & aims: </strong>Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver condition that is closely associated with inflammatory bowel disease (IBD). PSC is associated with substantial long-term hepatobiliary morbidity, including an increased risk of cholangiocarcinoma. Reported prevalence and incidence estimates of PSC vary widely across different populations and study designs. This meta-analysis aims to provide an updated estimate of the prevalence of PSC in the general and IBD populations, and PSC incidence in the general population.</p><p><strong>Methods: </strong>A systematic search of MEDLINE (Ovid) and Embase from inception to October 20, 2025, for population- or cohort-based studies reporting PSC prevalence or incidence was performed. Seventy-four studies met the inclusion criteria. Random-effects meta-analyses were performed to pool prevalence and incidence estimates. Subgroup analyses, meta-regression, and sensitivity analyses were conducted to assess robustness and sources of heterogeneity.</p><p><strong>Results: </strong>Seventeen studies including 196,635,709 individuals showed a pooled overall PSC prevalence of 8.06 per 100,000 (95% CI 4.75-13.36) in the general population. Among 516,548 patients with IBD in thirty-four studies, pooled PSC prevalence was 15.2 per 1,000 (95% CI 10.7-21.7). PSC prevalence was higher in ulcerative colitis (20.6 per 1,000) than in Crohn's disease (10.2 per 1,000). Using Crohn's disease as the reference group, ulcerative colitis was associated with higher odds of PSC (OR 1.787, 95% CI 1.066-2.996, p = 0.028). Thirteen studies reported a pooled incidence of PSC in the general population of 0.892 per 100,000 person-years (95% CI 0.705-1.130).</p><p><strong>Conclusion: </strong>This meta-analysis provides an updated synthesis of PSC epidemiology, extending prior work by incorporating detailed subgroup analyses across IBD phenotype, PSC subtype, geographic region, socioeconomic context, diagnostic modality, case-ascertainment method, and time period, which are dimensions not comprehensively addressed in previous meta-analyses. PSC remains a rare disease in the general population but is substantially more prevalent among individuals with IBD. Marked geographic and methodological heterogeneity, with notable underrepresentation of data from lower-SDI regions and the African Region, underscores the need for standardized case definitions and improved epidemiological surveillance across diverse settings. Given the markedly increased risk of cholangiocarcinoma in PSC, these findings highlight the clinical importance of recognizing PSC in higher-risk IBD populations and provide an epidemiological foundation for future studies evaluating risk stratification, early detection, and surveillance.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1463-1478"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-07-27DOI: 10.1007/s12072-026-11133-0
Thomas Sorz-Nechay, Benedikt S Hofer, Philipp Königshofer, Alexis Treitler, Georg Semmler, Benedikt Simbrunner, Vlad Taru, Katharina Bonitz, Henriette Horstmeier, Georg Kramer, Kerstin Zinober, Katharina Regnat, Barbara Neudert, Christopher C Kaltenecker, Behrang Mozayani, Renate Kain, Michael Trauner, Mattias Mandorfer, Philipp Schwabl, Thomas Reiberger
{"title":"Histomorphometry indicates distinct contributions of myofibroblast activation and sinusoidal capillarization to portal hypertension.","authors":"Thomas Sorz-Nechay, Benedikt S Hofer, Philipp Königshofer, Alexis Treitler, Georg Semmler, Benedikt Simbrunner, Vlad Taru, Katharina Bonitz, Henriette Horstmeier, Georg Kramer, Kerstin Zinober, Katharina Regnat, Barbara Neudert, Christopher C Kaltenecker, Behrang Mozayani, Renate Kain, Michael Trauner, Mattias Mandorfer, Philipp Schwabl, Thomas Reiberger","doi":"10.1007/s12072-026-11133-0","DOIUrl":"10.1007/s12072-026-11133-0","url":null,"abstract":"<p><strong>Background and aims: </strong>Portal hypertension (PH) is a severe consequence of cirrhosis and the primary driver of hepatic decompensation. We aimed to investigate the link between histological myofibroblast activation (alpha-smooth-muscle-actin: αSMA) and sinusoidal capillarization (CD34) markers to PH severity in patients with chronic liver disease (CLD).</p><p><strong>Methods: </strong>Patients with CLD underwent hepatic venous pressure gradient (HVPG) measurement and liver biopsy. Liver samples were stained by picrosirius-red for collagen proportionate area (CPA) and for αSMA/CD34. Quantitative histomorphometry was performed on full-slide scans.</p><p><strong>Results: </strong>102 patients (63.7% male, median age 56.4 years, mainly steatotic liver disease: 58.8%) were included. The median HVPG was 13 [10-18] mmHg and severe PH (HVPG ≥ 16 mmHg, PH16) was found in 35.3%. Median liver-stiffness was 30.6 [19.1-57.6] kPa. In PH16 patients, fibrosis (CPA: 28.39 vs 17.72%), myofibroblast activation (αSMA: 10.84 vs 3.75%), and capillarization (CD34: 5.45 vs 2.67%) were significantly more pronounced (all p < 0.001 vs. no PH16). CD34 showed a higher correlation to HVPG (rho = 0.505) than CPA (rho = 0.472) and αSMA (rho = 0.347, all p < 0.001). CD34 expression was independently correlated with enhanced liver fibrosis (ELF) test and von Willebrand factor (VWF). When partially adjusting for fibrosis severity, patients with less severe fibrosis and high αSMA or CD34 had a trend for higher HVPG, whereas in intermediate fibrosis, only CD34-high patients trended higher HVPG.</p><p><strong>Conclusion: </strong>CPA, CD34 and αSMA expression all correlate with PH severity. CD34 represents a histologic sinusoidal capillarization marker that correlates with circulating VWF and ELF. αSMA and CD34 represent potential histologic markers of PH beyond the static component.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1432-1445"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-05-22DOI: 10.1007/s12072-026-11097-1
Dhiraj Agrawal, Dinesh Jothimani, Sherrie Bhoori, Guru N Reddy, Sanjiv Saigal, Mohamed Rela, Vincenzo Mazzaferro
{"title":"Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child-Turcotte-Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression.","authors":"Dhiraj Agrawal, Dinesh Jothimani, Sherrie Bhoori, Guru N Reddy, Sanjiv Saigal, Mohamed Rela, Vincenzo Mazzaferro","doi":"10.1007/s12072-026-11097-1","DOIUrl":"10.1007/s12072-026-11097-1","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) have revolutionized advanced hepatocellular carcinoma (HCC) outcomes in Child-Turcotte-Pugh A (CTP-A) cirrhosis. However, 30-40% of real-world advanced HCC cases involve CTP-B cirrhosis, yet are excluded from pivotal trials, representing a substantial unmet need.</p><p><strong>Methods: </strong>Immunotherapy for CTP-B HCC has not yet been comprehensively reviewed. This narrative review summarizes the latest evidence on ICIs in CTP-B HCC through January 2026, evaluating ICI efficacy, safety, and patient selection algorithms across CTP-B subclasses. We present a balanced perspective on pre-ICI portal hypertension screening/prophylaxis, decompensation triggers/recompensation strategies, immune-mediated hepatitis differentiation, locoregional therapy sequencing, and transplant-bridging risks with ICI in the CTP-B patient population.</p><p><strong>Results: </strong>ICIs demonstrate modest efficacy with tolerable safety in well-selected CTP-B7-B8 HCC patients, but require liver-centric considerations to mitigate the risk of decompensation. We propose liver-centric trial endpoints and a multidisciplinary (oncology-hepatology-transplant) framework to improve outcomes in this hard-to-treat population, and to include CTP-B HCC patients in clinical trials to address evidence gaps.</p><p><strong>Conclusions: </strong>This review provides comprehensive guidance on ICIs for CTP-B HCC, identifying key clinical practices and knowledge gaps to inform real-world use and future research.</p>","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1299-1317"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147987230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-06-23DOI: 10.1007/s12072-026-11113-4
Xuyang Liu, Ze Bo, Yanchen Zhong, Mingshan Liu
{"title":"Beyond \"left or right\": future implications for study design and endpoints in TIPS portal branch selection.","authors":"Xuyang Liu, Ze Bo, Yanchen Zhong, Mingshan Liu","doi":"10.1007/s12072-026-11113-4","DOIUrl":"10.1007/s12072-026-11113-4","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1559-1560"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148307807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatology InternationalPub Date : 2026-10-01Epub Date: 2026-04-01DOI: 10.1007/s12072-026-11081-9
Jing Han, Di Qiang, Shasha Qiu, Liming Lou
{"title":"Methodological and safety considerations for combination immunotherapy and NA cessation in CHB.","authors":"Jing Han, Di Qiang, Shasha Qiu, Liming Lou","doi":"10.1007/s12072-026-11081-9","DOIUrl":"10.1007/s12072-026-11081-9","url":null,"abstract":"","PeriodicalId":12901,"journal":{"name":"Hepatology International","volume":" ","pages":"1557-1558"},"PeriodicalIF":7.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}